Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology has released its Q3 2024 financial results and corporate updates. Key highlights include the expected topline results from the registration-directed trial of ziftomenib in R/R NPM1-mutant AML in early 2025. Additionally, data from 100 patients in the Phase 1a study of ziftomenib will be presented at the ASH Annual Meeting. The Phase 1b expansion study of ziftomenib is now enrolling at 600 mg across all cohorts. Preclinical data supports the potential of ziftomenib in GIST, with a proof-of-concept study expected in 1H 2025. The first patient has been dosed in the study of KO-2806 and adagrasib in KRASG12C-mutated NSCLC. Financially, Kura reported a net loss of $54.4 million for Q3 2024, compared to $38.6 million in Q3 2023. R&D expenses rose to $41.7 million from $29.3 million, and G&A expenses increased to $18.2 million from $13.1 million. The company holds $455.3 million in cash, cash equivalents, and investments, expected to fund operations into 2027.
Kura Oncology (KURA) announced two abstracts from the KOMET-007 combination trial of ziftomenib will be presented at the ASH Annual Meeting in San Diego (December 7-10, 2024). The trial combines ziftomenib with standard treatments in NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) patients.
Key highlights include: All four Phase 1a dose-escalation cohorts advanced to Phase 1b expansion at 600 mg; 100% of NPM1-m AML patients and 84% of KMT2A-r patients remained on study; No DLTs or ziftomenib-induced QTc prolongation reported. The data suggests promising safety profile and robust activity in combination with standard treatments.
Kura Oncology (Nasdaq: KURA) announced it will release its third quarter 2024 financial results after U.S. market close on Thursday, November 7, 2024. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day, featuring management's discussion of financial results and a corporate update. Investors can access the call via phone or watch the webcast through the company's website.
Cartography Biosciences has appointed Troy E. Wilson, Ph.D., J.D. as an independent director to its Board of Directors. Wilson, a 25-year biopharma industry veteran, is currently President, CEO, and co-founder of Kura Oncology (NASDAQ: KURA). He brings extensive experience in founding and leading biotech companies, including Avidity Biosciences, Araxes Pharma, and Wellspring Biosciences. Cartography, an oncology company developing antibody therapeutics, aims to leverage Wilson's expertise as it advances its pipeline of novel programs targeting tumors more precisely than existing treatments.
Kura Oncology (KURA) reported promising preclinical data for its menin inhibitor ziftomenib in treating gastrointestinal stromal tumors (GIST). The combination of ziftomenib and imatinib demonstrated robust antitumor activity in both imatinib-sensitive and resistant GIST models. The data shows the combination works through a synthetic lethal mechanism, with ziftomenib targeting epigenetic vulnerabilities in GIST tumors. Following FDA clearance of the IND application in August 2024, Kura plans to initiate a proof-of-concept study combining ziftomenib with imatinib in advanced GIST patients after imatinib failure in 1H 2025.
Kura Oncology (Nasdaq: KURA) announced upcoming presentations of new preclinical data for its next-generation farnesyl transferase inhibitor (FTI) KO-2806 at the EORTC-NCI-AACR Symposium in Barcelona. The data supports combining KO-2806 with KRASG12C inhibitors and pan-RAS inhibitors for cancer treatment.
Two presentations will showcase how KO-2806 can re-sensitize KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors and sensitize colorectal cancers to pan-RAS inhibition. The company believes KO-2806 could enhance antitumor activity and become a valuable combination partner for targeted therapies in large solid tumor indications.
Kura Oncology (Nasdaq: KURA) has announced the publication of its KOMET-001 Phase 1 study results for ziftomenib in The Lancet Oncology. The study evaluated the safety, tolerability, and clinical activity of ziftomenib in relapsed/refractory acute myeloid leukemia (AML). Key findings include:
1. Promising clinical activity with manageable toxicity in heavily pretreated patients.
2. Marrow blast reduction, neutrophil and platelet recovery, transfusion independence, and clearance of measurable residual disease.
3. Determination of the recommended phase 2 dose (RP2D).
The company has completed enrollment for the Phase 2 portion of KOMET-001, a registration-directed trial in patients with NPM1-mutant AML. Topline data from this trial is expected in early 2025.
Kura Oncology (Nasdaq: KURA) has appointed Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience to the clinical-stage biopharmaceutical company. He currently serves as a Senior Advisor at Frazier Healthcare Partners and has held executive positions at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, Genzyme, and Sanofi Oncology.
The appointment comes at a key inflection point for Kura Oncology as it advances its menin inhibitor and farnesyl transferase inhibitor (FTI) programs for cancer treatment. Dr. Vasconcelles' expertise in R&D, regulatory affairs, and leadership across various companies is expected to be valuable in progressing these therapies through clinical trials and towards commercialization.
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in the upcoming Cantor Global Healthcare Conference in New York. The company's President and CEO, Troy Wilson, Ph.D., J.D., is set to take part in a fireside chat on September 17, 2024, at 1:20 p.m. ET / 10:20 a.m. PT.
Interested parties can access a live audio webcast of the fireside chat through the investor section of Kura's website at www.kuraoncology.com. An archived replay will also be available after the live event concludes. This conference participation provides an opportunity for Kura Oncology to showcase its progress and engage with the healthcare investment community.
Kura Oncology (Nasdaq: KURA) reported Q2 2024 financial results and provided a corporate update. Key highlights:
- Completed enrollment in KOMET-001 trial of ziftomenib in R/R NPM1-mutant AML; topline data expected in early 2025
- Received Breakthrough Therapy Designation for ziftomenib in R/R NPM1-mutant AML
- Phase 1b expansion study of ziftomenib combinations now enrolling
- IND cleared for ziftomenib in GIST; proof-of-concept study to begin in early 2025
- First patient dosed in KO-2806 and adagrasib combination study in NSCLC
- $491.5 million cash runway into 2027
Q2 2024 financials: R&D expenses $39.7M, G&A expenses $16.7M, net loss $50.8M
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
